Cover Image
市場調查報告書

T細胞表面糖蛋白CD4:開發中產品分析

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 367834
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
T細胞表面糖蛋白CD4:開發中產品分析 T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2018
出版日期: 2018年05月22日 內容資訊: 英文 70 Pages
簡介

本報告提供以T細胞表面糖蛋白CD4為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

T細胞表面糖蛋白CD4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Biotest AG
  • CEL-SCI Corporation
  • Fountain Biopharma Inc.
  • Immupharma Plc
  • Inovio Pharmaceuticals, Inc.
  • TaiMed Biologics Inc.
  • United Biomedical, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1463TDB

Summary

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu.

The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Cardiovascular and Central Nervous System which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Autoimmune Disorders, Encephalitis, Graft Versus Host Disease (GVHD), Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox, Systemic Lupus Erythematosus and West Nile Virus Infections.

Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
  • Biotest AG
  • Bristol-Myers Squibb Co
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • Sanofi
  • TaiMed Biologics Inc
  • United Biomedical Inc
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
  • Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CEL-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • forigerimod acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ibalizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ibalizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-48U1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MAX-16H5 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • N-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate CD4 for HIV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMB-360 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMB-365 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tregalizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • UB-421 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
  • T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.
  • Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference
  • Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe
  • Apr 17, 2018: ImmuPharma announces Top line results of Lupuzor Pivotal Phase III Trial
  • Mar 23, 2018: ImmuPharma: Lupuzor Pivotal Phase III Study Update
  • Mar 15, 2018: United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trial
  • Mar 08, 2018: Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection
  • Mar 07, 2018: New Positive Data on Trogarzo (ibalizumab-uiyk) Injection Presented at 25th Conference on Retroviruses and Opportunistic Infections
  • Mar 07, 2018: WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo
  • Mar 06, 2018: FDA Approves New HIV Treatment for Patients who have Limited Treatment Options
  • Mar 06, 2018: Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1
  • Jan 18, 2018: ImmuPharma Announces Completion of Lupuzor Pivotal Phase III Study and Initiation of Follow Up Study
  • Dec 21, 2017: Last patient completes dosing in Lupuzor Pivotal Phase III Study
  • Nov 13, 2017: Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018
  • Nov 02, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study2017
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Biotest AG, H1 2018
  • Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Pipeline by CEL-SCI Corp, H1 2018
  • Pipeline by Fountain Biopharma Inc, H1 2018
  • Pipeline by Immupharma Plc, H1 2018
  • Pipeline by Sanofi, H1 2018
  • Pipeline by TaiMed Biologics Inc, H1 2018
  • Pipeline by United Biomedical Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top